Cancer scientists overestimate the extent to which high-profile preclinical studies can be successfully replicated, new research from McGill University suggests.
Canadian researchers have invented an intraoperative probe that reliably detects multiple types of tumour cells
Patients with common widespread forms of cancer will enjoy longer life expectancy and reduced risk of recurrence thanks to a multimodal optical spectroscopy probe developed by Canadian researchers.
Does the biological clock in cancer cells influence tumour growth? Yes, according to a study conducted by Nicolas Cermakian, a professor in McGill University’s Department of Psychiatry.
Published in the journal BMC Biology, these results show for the first time that directly targeting the biological clock in a cancerous tumour has an impact on its development.
A team of researchers at the Research Institute of the McGill University Health Centre (RI-MUHC) has found an epigenetic modification that might be the cause of 15% of adult cancers of the throat linked to alcohol and tobacco use. This is a first in the field of epigenetics and the researchers are hopeful that the discovery can blaze a path in the development of new, targeted, more effective treatments that could arise over the next few years.
Just four weeks of prehabilitation (pre-surgery preparation) may be enough to help some cancer patients get in shape for surgery. That’s according to a recent study of close to 120 colorectal cancer patients in Montreal. This potentially means that, barring unforeseen circumstances that stem from the surgery itself, their recovery is likely to be speedier too, according to earlier research from the same McGill-led team.
A receptor for the dopamine neurotransmitter promotes growth and spread of pancreatic cancer -- and schizophrenia drugs, which block the function of this receptor, slowed tumor growth and metastatic spread in mice, according to researchers at McGill University and the German Cancer Research Center.
Study reveals the impact of night work
You cross paths with him at the break of dawn in the corridors of the Metro. He looks bleary-eyed and pallid. This worker’s night shift just ended. His body clocks are out of sync with one another, and, imperceptibly, they’re also out of sync with his environment. In the long run, this night owl could be at greater risk of developing cardiovascular, autoimmune diseases or certain types of cancer.
Newly named Gerald Bronfman Department of Oncology recognizes family’s enduring support
In recognition of the Bronfman family’s enduring support for oncology programs and research at McGill University, the Faculty of Medicine’s Department of Oncology has been named the Gerald Bronfman Department of Oncology, in honour of one of the family’s major benefactors.
Pioneering research at McGill’s Goodman Cancer Research Centre gets boost
The 4th Goodman Cancer Research Gala has raised more than $2.1 million to fund foundational research, more effective diagnostic tools and the development of new treatments and therapies for cancer patients. The Gala was held on Sunday, June 5 in Montreal, bringing together more than 800 guests in support of McGill University’s Rosalind and Morris Goodman Cancer Research Centre.
By Tod Hoffman, Lady Davis Institute for Medical Research
The use of incretin-based drugs is not associated with an increased risk of pancreatic cancer in patients with type 2 diabetes, according to a study published in the latest issue of the British Medical Journal (BMJ).
The research was conducted by the Canadian Network for Observational Drug Effect Studies (CNODES), which used the health records of almost 1 million patients with types 2 diabetes.
Preventing cancer cells from growing by understanding what they 'eat'.
It is estimated that half of all cancer patients suffer from a muscle wasting syndrome called cachexia. Cancer cachexia impairs quality of life and response to therapy, which increases morbidity and mortality of cancer patients. Currently, there is no approved treatment for muscle wasting but a new study from the Research Institute of the McGill University Health Centre (RI-MUHC) and University of Alberta could be a game changer for patients, improving both quality of life and longevity. The research team discovered a new gene involved in muscle wasting that could be a good target for drug development.